{"id":"ad109-dose2-b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3805013","moleculeType":"Small molecule","molecularWeight":"253.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AD109 works by selectively binding to the orexin receptor, which is involved in the regulation of sleep-wake cycles. This binding leads to a decrease in orexin signaling, resulting in improved sleep quality and reduced excessive daytime sleepiness. By modulating the orexin system, AD109 aims to provide a more effective treatment for narcolepsy.","oneSentence":"AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:08.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT04631107","phase":"PHASE2","title":"AD109 Dose Finding in Mild to Moderate OSA","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-12-22","conditions":"Obstructive Sleep Apnea","enrollment":32},{"nctId":"NCT05128591","phase":"PHASE1","title":"A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-09","conditions":"Embolism and Thrombosis","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AD109 37.5"],"phase":"phase_2","status":"active","brandName":"AD109 dose2- B","genericName":"AD109 dose2- B","companyName":"Apnimed","companyId":"apnimed","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy. Used for Narcolepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}